| Abstract |
Background: Bone marrow involvement in lymphoma indicates stage IV disease and may affect both treatment and prognosis. Aim and Objective: The aim of the present study was to compare 18 F 2-fluoro-2-deoxy- glucose (FDG) positron emission tomography/ computered tomography (PET/CT) with bone marrow biopsy (BMB) in the initial evaluation of bone marrow (BM) involvement in lymphoma (HL&NHL) patients. Material and Methods: Patients with biopsy confirmed newly diagnosed lymphoma, during the period between May 2013 and December 2014 were included. The sensitivity, specificity, positive predictive value and negative predictive value of PET/CT was calculated and compared with bone marrow biopsy. Results: Out of the 60 patients 18 were diagnosed with Hodgkin’s lymphoma and 42 with Non-Hodgkin’s lymphoma. The sensitivity, specificity, positive predictive value and negative predictive value of PET/CT in Hodgkin lymphoma was 100%, 58.82%, 12.5%, 100% respectively. The sensitivity, specificity, positive predictive value and negative predictive value of PET/CT in Non-Hodgkin lymphoma was 90.91%, 77.42%,58.82%,96% respectively. Conclusion:18F FDG/PET had high sensitivity in detecting bone marrow involvement in Hodgkin’s lymphoma than in non-Hodgkin’s lymphoma. In Hodgkin’s lymphoma it could replace blind iliac crest BMB. In Non-Hodgkin’s lymphoma it plays a complimentary role with BMB in the staging.
KEYWORDS: Lymphoma, bone marrow biopsy, PET/CT. |
